

MARKET REPORT



PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023

Summary

The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023. The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti and daratumumab, which will not only provide a new treatment option for MM patients, but will also lengthen the time between relapses, meaning that the duration of Revlimid and/or Velcade treatments will also be longer. Furthermore, the relatively mild safety profile of these mAbs and the significant efficacies demonstrated by these agents will mean that more MM patients will ultimately receive drug treatment. Label extensions of these mAbs, as well as of second-generation proteasome inhibitors ixazomib and Kyprolis, will further increase treatment options for these patients. The biggest constrainers of the MM market are the increasing cost-consciousness of healthcare providers, as the launch and subsequent label extensions of these pipeline agents will lead to a significant expense, which may impact uptake of these drugs. The patent expiries of Revlimid and Velcade will somewhat alleviate healthcare spending on multiple myeloma patients, which may assist in the uptake of mAbs and second-generation PIs in the multiple myeloma market.

Highlights

Key Questions Answered

- The multiple myeloma market is marked by the presence of a number of unmet needs. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of multiple myeloma market?
- The late-stage multiple myeloma pipeline has therapies targeting different multiple myeloma populations. Which late-stage drugs will have the biggest impact in each patient population? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- The current multiple myeloma market is dominated by Velcade and Revlimid. How will the advent of new mAbs change the drug treatment landscape for multiple myeloma? How will the drug treatment rate change over the next five years? What are the key drivers and barriers to this change?

Key Benefits

- The main driver of the enormous expansion of the multiple myeloma market will be the launch of mAbs Empliciti and daratumumab.
- The second largest driver will be the label extension of currently marketed drugs Kyprolis and Revlimid.
- Another driver of the multiple myeloma market will be the ageing population in the 8MM, which will increase the number of multiple myeloma cases.
- The increase in therapeutic options overall will lead to increases in treatment rates in the 8MM. Also, as triplet/quadruplet therapies increasingly become the standard of care within the forecast period, this will increase the duration of treatment for each patient as well as the number of treatments each patient receives.

Scope

- Overview of multiple myeloma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized multiple myeloma therapeutics market revenue, average cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the multiple myeloma therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global multiple myeloma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global multiple myeloma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global multiple myeloma therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global multiple myeloma therapeutics market from 2013-2023.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Additional Details

Publisher : Global Data
Reference : GDHC114PIDR
Number of Pages : 262
Report Format : PDF
Publisher Information :

GlobalData»

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023

- 1 Table of Contents1 Table of Contents 111.1 List of Tables 171.2 List of Figures 232 Introduction 252.1 Catalyst 252.2 Related Reports 262.3 Upcoming Related Reports 263 Disease Overview 273.1 Etiology and Pathophysiology 273.1.1 Etiology 273.1.2 Pathophysiology 273.2 Staging Systems 303.3 Response and Relapse Criteria 313.4 Symptoms 333.5 Prognosis 343.6 Quality of Life 354 Epidemiology 384.1 Disease Background 384.2 Risk Factors and Comorbidities 394.3 Global Trends 404.3.1 Incidence 404.3.2 Survival Rates for Multiple Myeloma - 8MM 434.4 Forecast Methodology 444.4.1 Sources Used 464.4.2 Sources Not Used 484.4.3 Forecast Assumptions and Methods, Multiple Myeloma Diagnosed Incident Cases 484.4.4 Forecast Assumptions and Methods, Multiple Myeloma Five-Year Diagnosed Prevalent Cases 494.4.5 Forecast Assumptions and Methods, Multiple Myeloma Clinical Stages at Diagnosis 504.5 Epidemiological Forecast for Multiple Myeloma (2013-2023) 504.5.1 Diagnosed Incident Cases of Multiple Myeloma 504.5.2 Age-Specific Diagnosed Incident Cases of Multiple Myeloma 524.5.3 Sex-Specific Diagnosed Incident Cases of Multiple Myeloma 544.5.4 Age-Standardized Diagnosed Incidence of Multiple Myeloma 564.5.5 Diagnosed Incident Cases of Multiple Myeloma by Clinical Stage at Diagnosis 574.5.6 Five-Year Diagnosed Prevalent Cases of Multiple Myeloma 584.6 Discussion 604.6.1 Epidemiological Forecast Insight 604.6.2 Limitations of the Analysis 604.6.3 Strengths of the Analysis 615 Disease Management 625.1 Treatment Overview 625.2 Diagnosis 635.3 Clinical Practice 645.3.1 Primary Therapy for SCT-Eligible Patients 655.3.2 Primary Therapy for Non-SCT Patients 675.3.3 Salvage/Relapse Therapy 685.3.4 Leading Prescribed Drugs 695.4 US 715.4.1 Diagnosis 725.4.2 Clinical Practice 735.5 France 755.5.1 Diagnosis 765.5.2 Clinical Practice 775.6 Germany 775.6.1 Diagnosis 795.6.2 Clinical Practice 795.7 Italy 795.7.1 Diagnosis 815.7.2 Clinical Practice 815.8 Spain 835.8.1 Diagnosis 845.8.2 Clinical Practice 845.9 UK 855.9.1 Diagnosis 865.9.2 Clinical Practice 875.10 Japan 875.10.1 Diagnosis 885.10.2 Clinical Practice 895.11 China (Urban) 905.11.1 Diagnosis 915.11.2 Clinical Practice 926 Competitive Assessment 936.1 Overview 936.2 Product Profiles - Proteasome Inhibitors 936.2.1 Velcade (Bortezomib) 936.2.2 Kyprolis (Carfilzomib) 1006.3 Product Profiles - Immunomodulators 1086.3.1 Revlimid (Lenalidomide) 1086.3.2 Pomalyst/Imnovid (Pomalidomide) 1156.4 Other Therapeutic Classes 1207 Unmet Need and Opportunity 1217.1 Overview 1217.2 Treatment of High-Risk Patients 1217.2.1 Unmet Need 1217.2.2 Gap Analysis 1227.2.3 Opportunity 1237.3 Treatment of Patients with Smoldering Myeloma 1237.3.1 Unmet Need 1237.3.2 Gap Analysis 1257.3.3 Opportunity 1257.4 Treatment of Extramedullary Disease 1267.4.1 Unmet Need 1267.4.2 Gap Analysis 1267.4.3 Opportunity 1278 Pipeline Assessment 1288.1 Overview 1288.2 Promising Drugs in Clinical Development 1288.2.1 Farydak (Panobinostat) 1288.2.2 Ixazomib 1358.2.3 Emluciti (Elotuzumab) 1408.2.4 Daratumumab 1468.2.5 Aplidin (Plitidepsin) 1518.3 Promising Drugs in Early-Stage Development 1558.3.1 Oprozomib (ONX-0912) 1558.3.2 Filanesib 1568.3.3 SAR650984 1568.3.4 Marizomib 1588.3.5 Evofosfamide 1588.3.6 LGH447 1598.3.7 Selinexor (KPT-330) 1599 Current and Future Players 1619.1 Overview and Trends in Corporate Strategy 1619.2 Company Profiles 1649.2.1 Millennium Pharmaceuticals/Takeda 1649.2.2 Celgene 1669.2.3 Onyx Pharmaceuticals/Amgen 1689.2.4 Novartis 1699.2.5 AbbVie 1719.2.6 Bristol-Myers Squibb 1729.2.7 Janssen 17310 Market Outlook 17510.1 Global Markets 17510.1.1 Forecast 17510.1.2 Drivers - Global Issues 18210.1.3 Barriers - Global Issues 18310.2 US 18410.2.1 Forecast 18410.2.2 Key Events 18810.2.3 Drivers - US 18810.2.4 Barriers - US 19010.3 5EU 19110.3.1 Forecast 19110.3.2 Key Events 19610.3.3 Drivers - 5EU 19610.3.4 Barriers - 5EU 19810.4 Japan 20010.4.1 Forecast 20010.4.2 Key Events 20310.4.3 Drivers - Japan 20310.4.4 Barriers - Japan 20410.5 China (Urban) 20510.5.1 Forecast 20510.5.2 Key Events 20810.5.3 Drivers - China (Urban) 20810.5.4 Barriers - China (Urban) 20911 Appendix 21111.1 Bibliography 21111.2 Abbreviations 23311.3 Methodology 23711.4 Forecasting Methodology 23711.4.1 Diagnosed Multiple Myeloma Patients 23711.4.2 Percent of Drug-Treated Patients 23811.4.3 Drugs Included in Each Therapeutic Class 23811.4.4 Launch and Patent Expiry Dates 23911.4.5 General Pricing Assumptions 24011.4.6 Individual Drug Assumptions 24111.4.7 Pricing of Pipeline Agents 24811.4.8 Generic Erosion 25511.5 Primary Research - KOLs Interviewed for this Report 25611.6 Primary Research - High-Prescriber Survey 25811.7 About the Authors 25911.7.1 Analyst 25911.7.2 Therapy Director 25911.7.3 Epidemiologist 25911.7.4 Global Head of Healthcare 26011.8 About GlobalData 26111.9 Disclaimer 261

List Of Tables in PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023

1.1 List of Tables

Table 1: Definition of the Classes of Myeloma 29

Table 2: Staging Systems for Multiple Myeloma 31

Table 3: IMWG Uniform Response Criteria for Multiple Myeloma: Response 32

Table 4: IMWG Uniform Response Criteria for Multiple Myeloma: Progression 32

Table 5: Symptoms of Multiple Myeloma 33

Table 6: Median Survival for Each Stage at Diagnosis of Multiple Myeloma 34

Table 7: Potential Diagnostic Markers that Predict Two-Year Disease Progression 35

Table 8: Summary of Prevalence and Clinical Outcomes of Translocations in Multiple Myeloma 35

Table 9: Multiple Myeloma Clinical Stages at Diagnosis, Using the ISS Criteria 39

Table 10: Risk Factors and Comorbidities for Multiple Myeloma 40

Table 11: Trends in the Age-Adjusted Incidence of Multiple Myeloma in the US, Ages ≥ 40 Years, 1993-2007 41

Table 12: Trends in the Age-Adjusted Incidence of Multiple Myeloma in the 5EU, Ages ≥ 40 Years, 1993-2007 42

Table 13: Trends in the Age-Adjusted Incidence of Multiple Myeloma in Japan, Ages ≥ 40 Years, 1993-2007 42

Table 14: Trends in the Age-Adjusted Incidence of Multiple Myeloma in Urban China, Ages ≥ 40 Years, 1993-2007 43

Table 15: Trends in the Five-Year Relative Survival (%) of Multiple Myeloma in the 8MM, Both Sexes, 1993-2009 44

Table 16: 8MM, Sources of Epidemiological Data Used for the Forecast for Multiple Myeloma Diagnosed Incident Cases 45

Table 17: 8MM, Sources of Epidemiological Data Used for the Forecast for Multiple Myeloma Diagnosed Five-Year Prevalent Cases 45

Table 18: 8MM, Sources of Epidemiological Data Used for the Segmentation of Multiple Myeloma Incident Cases by Clinical Stage at Diagnosis 46

Table 19: 8MM, Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, Ages ≥ 40 Years, N, 2013-2023 51

Table 20: 8MM, Age-Specific Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, N (Row %), 2013 53

Table 21: 8MM, Sex-Specific Diagnosed Incident Cases of Multiple Myeloma, Ages ≥ 40 Years, N (Row %), 2013 55

Table 22: 8MM, Five-Year Diagnosed Prevalent Cases of Multiple Myeloma, Both Sexes, Ages ≥ 40 Years, N, 2013-2023 59

Table 23: Treatment Guidelines for Multiple Myeloma 63

Table 24: Definition of the Classes of Myeloma	64
Table 25: Most Prescribed Drugs for Multiple Myeloma by Class in the Global Markets, 2014	69
Table 26: Most-Prescribed Drugs for Multiple Myeloma by Segment in the Global Markets, 2013	70
Table 27: Country Profile - US	72
Table 28: Country Profile - France	75
Table 29: Country Profile - Germany	78
Table 30: Country Profile - Italy	80
Table 31: Country Profile - Spain	83
Table 32: Country Profile - UK	86
Table 33: Country Profile - Japan	88
Table 34: Country Profile - China (Urban)	91
Table 35: Product Profile - Velcade	94
Table 36: Results from the Pivotal Phase III APEX Trial for Velcade	96
Table 37: Results from the Pivotal Phase III VISTA Trial for Velcade	97
Table 38 Results from the Subcutaneous versus Intravenous Velcade Phase III trial	97
Table 39: Common Grade 3 and 4 Adverse Events from Velcade Pivotal Clinical Trials	98
Table 40: Velcade SWOT Analysis, 2015	99
Table 41: Global Sales Forecast (\$m) for Velcade, 2013-2023	99
Table 42: Product Profile - Kyprolis	101
Table 43 Summary of Phase III Pivotal Trial Results for Kyprolis	104
Table 44: Summary of Phase II Clinical Trial Efficacy Data for Kyprolis	105
Table 45 Summary of Adverse Events from Key Phase III Pivotal Trials for Kyprolis	106
Table 46: Kyprolis SWOT Analysis, 2015	107
Table 47: Global Sales Forecasts (\$m) for Kyprolis, 2013-2023	108
Table 48: Product Profile - Revlimid	109
Table 49 Summary of Phase III Pivotal Trial Results for Revlimid in NDMM Patients	111
Table 50 Summary of Phase III Pivotal Trial Results for Revlimid in RRMM Patients	112
Table 51: Summary of Frequent Grade 3 and 4 AEs in a Phase III Trial for Revlimid	113
Table 52: Revlimid SWOT Analysis, 2015	114
Table 53: Global Sales Forecast (\$m) for Revlimid, 2013-2023	114
Table 54: Product Profile - Pomalyst	115

Table 55: Summary of PFS, OS, and ORR from Phase II Trial Data for Pomalyst 117
Table 56: Summary of Phase III Trial Data for Pomalyst 118
Table 57: Pomalyst SWOT Analysis, 2015 119
Table 58: Global Sales Forecasts (\$m) for Pomalyst, 2013-2023 119
Table 59: Summary of Other Therapeutic Classes, 2015 120
Table 60: Pipeline Product Profile - Farydak 129
Table 61: Summary of the Phase III PANORAMA 1 Trial of Farydak 132
Table 62: Summary of the Phase III PANORAMA 1 Trial of Farydak in Patients Who Received at Least Two Prior Lines of Therapy (Including Velcade and an IMiD) 132
Table 63: Summary of the Phase II PANORAMA 2 Trial of Farydak 133
Table 64: Grade 3-4 Adverse Events in the Phase III PANORAMA 1 Trial of Farydak 133
Table 65: Farydak SWOT Analysis, 2015 135
Table 66: Global Sales Forecast (\$m) for Farydak, 2013-2023 135
Table 67: Pipeline Product Profile - Ixazomib 136
Table 68: Response Results from the Phase II Study of Ixazomib 138
Table 69: Ixazomib SWOT Analysis, 2015 139
Table 70: Global Sales Forecast (\$m) for Ixazomib, 2013-2023 140
Table 71: Pipeline Product Profile - Empliciti 141
Table 72: Summary of the Phase III ELOQUENT 2 trial of Empliciti 143
Table 73: Efficacy Results from the Phase II Study of Empliciti with Velcade and Dexamethasone 144
Table 74: Empliciti SWOT Analysis, 2015 145
Table 75: Global Sales Forecast (\$m) for Empliciti, 2013-2023 145
Table 76: Pipeline Product Profile - Daratumumab 146
Table 77: Response Results from the Phase II Study of Daratumumab 148
Table 78: Daratumumab SWOT Analysis, 2015 150
Table 79: Global Sales Forecast (\$m) for Daratumumab, 2013-2023 150
Table 80: Pipeline Product Profile - Aplidin 151
Table 81: Summary of Phase II Clinical Trial Results for Aplidin 153
Table 82: Summary of Grade 3 and 4 Adverse Events of Aplidin 153
Table 83: Aplidin SWOT Analysis, 2015 154
Table 84: Global Sales Forecast (\$m) for Aplidin, 2013-2023 154

Table 85: Summary of Efficacy Data from the Phase Ib/II Clinical Trial of Oprozomib	156
Table 86: Summary of the Phase I Efficacy Results of SAR650984	157
Table 87: Summary of the Phase I Efficacy Results of Evofosfamide	159
Table 88: Key Companies in the Multiple Myeloma Market Across the 8MM, 2013-2023	162
Table 89: Millennium Pharmaceuticals Multiple Myeloma Therapy Portfolio Assessment, 2015	166
Table 90: Celgene's Multiple Myeloma Therapy Portfolio Assessment, 2015	168
Table 91: Onyx Pharmaceuticals Multiple Myeloma Therapy Portfolio Assessment, 2015	169
Table 92: Novartis' Multiple Myeloma Therapy Portfolio Assessment, 2015	171
Table 93: AbbVie's Multiple Myeloma Therapy Portfolio Assessment, 2015	172
Table 94: BMS' Multiple Myeloma Therapy Portfolio Assessment, 2015	173
Table 95: Janssen's Multiple Myeloma Therapy Portfolio Assessment, 2015	174
Table 96: Annual Global Sales (\$m) for Multiple Myeloma by Region, 2013-2023	176
Table 97: Annual Global Sales (\$m) for Multiple Myeloma by Drug, 2013-2023	179
Table 98: Global Multiple Multiple Myeloma - Drivers, 2013-2023	182
Table 99: Global Multiple Multiple Myeloma - Barriers, 2013-2023	183
Table 100: US Sales Forecast, Multiple Myeloma, 2013-2023 (\$m)	185
Table 101: Key Events Impacting Sales for Multiple Myeloma in the US, 2013-2023	188
Table 102: US Multiple Myeloma - Drivers, 2013-2023	188
Table 103: US Multiple Myeloma - Barriers, 2013-2023	190
Table 104: 5EU Sales Forecast, Multiple Myeloma, 2013-2023 (\$m)	192
Table 105: Key Events Impacting Sales for Multiple Myeloma in the 5EU, 2013-2023	196
Table 106: 5EU Multiple Myeloma - Drivers and Barriers, 2013-2023	196
Table 107: 5EU Multiple Myeloma - Barriers, 2013-2023	198
Table 108: Japan Sales Forecasts, Multiple Myeloma, 2013-2023 (\$m)	201
Table 109: Key Events Impacting Sales for Multiple Myeloma in Japan, 2013-2023	203
Table 110: Japanese Multiple Myeloma - Drivers, 2013-2023	203
Table 111: Japanese Multiple Myeloma - Barriers, 2013-2023	204
Table 112: China (Urban) Sales Forecast, Multiple Myeloma, 2013-2023 (\$m)	206
Table 113: Key Events Impacting Sales for Multiple Myeloma in China 2013-2023	208
Table 114: Chinese (Urban) Multiple Myeloma - Drivers, 2013-2023	208
Table 115: Chinese (Urban) Multiple Myeloma - Barriers, 2013-2023	209

Table 116: Multiple Myeloma Diagnosed Incidence, 2013-2023 238

Table 117: Multiple Myeloma Drugs and Pipeline agents, Launch Dates 239

Table 118: Multiple Myeloma Drugs and Pipeline agents, Anticipated Patent Expiries 240

Table 119: Average Cost of Therapy for Velcade 242

Table 120: Average Duration of Treatment (Weeks) for Velcade 242

Table 121: Average Cost of Therapy for Kyprolis (\$) 244

Table 122: Average Duration of Treatment (Weeks) for Kyprolis 244

Table 123: Average Cost of Therapy for Revlimid (\$) 245

Table 124: Average Duration of Treatment (Weeks) for Revlimid 246

Table 125: Average Cost of Therapy for Pomalyst/Imnovid (\$) 247

Table 126 Average Duration of Treatment (Weeks) for Pomalyst/Imnovid 247

Table 127: Average Cost of Therapy for Farydak (\$) 248

Table 128: Duration of Treatment (Weeks) for Farydak 249

Table 129: Average Cost of Therapy for Ixazomib (\$) 250

Table 130: Duration of Treatment (Weeks) for Ixazomib 250

Table 131: Average Cost of Therapy for Empliciti (\$) 251

Table 132: Duration of Treatment (Weeks) for Empliciti 252

Table 133: Average Cost of Therapy for Daratumumab (\$) 253

Table 134: Duration of Treatment (Weeks) for Daratumumab 254

Table 135: Average Cost of Therapy for Daratumumab (\$) 255

Table 136: Duration of Treatment (Weeks) for Daratumumab 255

Table 137: Numbers of Prescribers Surveyed in Each Country 258

List Of Figures, Charts and Diagrams in PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023

1.2 List of Figures

Figure 1: 8MM, Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, Ages ≥ 40 Years, N, 2013-2023 52

Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, N, 2013 54

Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of Multiple Myeloma, Ages ≥ 40 Years, N, 2013 56

Figure 4: 8MM, Age-Standardized Diagnosed Incidence of Multiple Myeloma (Cases per 100,000 Population), Ages ≥ 40 Years, by Sex, 2013 57

Figure 5: 8MM, Diagnosed Incident Cases of Multiple Myeloma by Clinical Stage at Diagnosis, Ages ≥ 40 Years, N, 2013 58

Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of Multiple Myeloma, Both Sexes, Ages ≥ 40 Years, N, 2013-2023 59

Figure 7: SCT-Eligible Typical Patient Journey 65

Figure 8: Non-SCT-Eligible Typical Patient Journey 67

Figure 9: Velcade's Phase III Development in Multiple Myeloma 95

Figure 10: Kyprolis's Phase III Development in Multiple Myeloma 102

Figure 11: Revlimid's Phase III Development in Multiple Myeloma 109

Figure 12: Pomalyst/Imnovid's Phase III Development in Multiple Myeloma 116

Figure 13: Farydak's Development in Multiple Myeloma 131

Figure 14: Dosing Schedule for Farydak 134

Figure 15: Ixazomib's Development in Multiple Myeloma 137

Figure 16: Empliciti's Development in Multiple Myeloma 141

Figure 17: Daratumumab's Development in Multiple Myeloma 148

Figure 18: Global Sales (\$m) of Branded Products for Multiple Myeloma by Company, 2013 - 2023 163

Figure 19: Company Portfolio Gap Analysis in Multiple Myeloma, 2013-2023 164

Figure 20: Annual Global Sales for Multiple Myeloma by Region, 2013-2023 177

Figure 21: Annual Global Sales for Multiple Myeloma by Region - 2013, 2023 178

Figure 22: Annual Global Sales for Multiple Myeloma by Drug, 2013-2023 180

Figure 23: Global Sales for Multiple Myeloma by Drug, 2013 - 2023 181

Figure 24: Annual US Sales for Multiple Myeloma by Drug, 2013-2023 186

Figure 25: US Sales for Multiple Myeloma by Drug, 2013 and 2023 187

Figure 26: Annual 5EU Sales for Multiple Myeloma by Region, 2013-2023 193

Figure 27: Annual 5EU Sales for Multiple Myeloma by Drug, 2013-2023 194

Figure 28: 5EU Sales for Multiple Myeloma by Drug, 2013 and 2023 195

Figure 29: Annual Japanese Sales for Multiple Myeloma by Drug, 2013-2023 201

Figure 30: Japanese Sales for Multiple Myeloma by Drug, 2013 and 2023 202

Figure 31: Annual Chinese (Urban) Sales for Multiple Myeloma by Drug, 2013-2023 206

Figure 32: Chinese (Urban) Sales for Multiple Myeloma by Drug, 2013 and 2023 207

How to Buy...

PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
<https://www.bioportfolio.co.uk/product/17995>

Option 2 - Request a Proforma Invoice
Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:
Job Title:
Your Email:
Your Contact Phone:
Company Name:
Address:
Post/Zip Code:
Country:
P.O. Number:
Any Other Instructions:

Pricing Options: (please tick one)
 \$10995 | Single User Price
 \$21990 | Site License Price
 \$32985 | Enterprise License Price

Payment Options: (please tick one)
 Online Credit Card (we will email you the invoice with a payment link)
 Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.